Influenza-associated pediatric mortality in the United States: Increase of Staphylococcus aureus coinfection

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
PEDIATRICS (Impact Factor: 5.3). 11/2008; 122(4):805-11. DOI: 10.1542/peds.2008-1336
Source: PubMed

ABSTRACT Pediatric influenza-associated death became a nationally notifiable condition in the United States during 2004. We describe influenza-associated pediatric mortality from 2004 to 2007, including an increase of Staphylococcus aureus coinfections.
Influenza-associated pediatric death is defined as a death of a child who is younger than 18 years and has laboratory-confirmed influenza. State and local health departments report to the Centers for Disease Control and Prevention demographic, clinical, and laboratory data on influenza-associated pediatric deaths.
During the 2004-2007 influenza seasons, 166 influenza-associated pediatric deaths were reported (n = 47, 46, and 73, respectively). Median age of the children was 5 years. Children often progressed rapidly to death; 45% died within 72 hours of onset, including 43% who died at home or in an emergency department. Of 90 children who were recommended for influenza vaccination, only 5 (6%) were fully vaccinated. Reports of bacterial coinfection increased substantially from 2004-2005 to 2006-2007 (6%, 15%, and 34%, respectively). S aureus was isolated from a sterile site or endotracheal tube culture in 1 case in 2004-2005, 3 cases in 2005-2006, and 22 cases in 2006-2007; 64% were methicillin-resistant S aureus. Children with S aureus coinfection were significantly older and more likely to have pneumonia and acute respiratory distress syndrome than those who were not coinfected.
Influenza-associated pediatric mortality is rare, but the proportion of S aureus coinfection identified increased fivefold over the past 3 seasons. Research is needed to identify risk factors for influenza coinfection with invasive bacteria and to determine the impact of influenza vaccination and antiviral agents in preventing pediatric mortality.

Download full-text


Available from: Anthony E Fiore, Oct 13, 2014
1 Follower
  • Source
    • "Rapamycin works by binding cytosolic FK-binding protein 12 (FKBP12) and together these form a complex that binds the mTOR complex 1 (mTORC1) [10] [11] [12] [13] [14] [15]. mTORC1 is a serine/threonine phosphokinase which functions as a redox sensor, regulates cell growth and proliferation [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Rapamycin suppresses the RAW264.7 macrophage mediated inflammatory response but in lower doses induces it. In the present study, we tested the suppression of the inflammatory response in the presence of mTOR 1 and 2 inhibitors, Torin and KU63794. Methods. RAW264.7 cells were stimulated for 18 hrs with 106 to 107 CFU/mL inocula of community-acquired- (CA-) MRSA isolate, USA400 strain MW2, in the presence of Vancomycin. Then, in sequential experiments, we added Torin, KU63794, and Rapamycin alone and in various combinations. Supernatants were collected and assayed for TNF, IL-1, IL-6, INF, and NO. Results. Rapamycin induces 10–20% of the inflammatory cascade at dose of 0.1 ng/mL and suppresses it by 60% at dose of 10 ng/mL. The induction is abolished in the presence of Torin KU63794. Torin and KU63794 are consistently suppressing cytokine production 50–60%. Conclusions. There is a differential response between Rapamycin (mTOR-1 inhibitor) and Torin KU63794 (mTOR 1 and 2 inhibitors). Torin and KU63794 exhibit a dose related suppression. Rapamycin exhibits a significant induction-suppression biphasic response. Knowledge of such response may allow manipulation of the septic inflammatory cascade for clinical advantages.
    04/2014; 2014:560790. DOI:10.1155/2014/560790
  • Source
    • "Unlike in adults, influenza pneumonia in children is usually a benign illness, and the mortality is low [23]. Secondary bacterial infection seems to be a more common complication of influenza infection in children [1] [23] [24]. Death certificate coding practices can highly influence mortality data trends. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. Surveillance for laboratory-confirmed influenza-associated deaths in children is used to monitor the severity of influenza at the population level and to inform influenza prevention and control policies. The goal of this study was to better estimate pediatric influenza mortality in New York state (NYS). Methods. Death certificate data were requested for all passively reported deaths and any pneumonia and influenza (P&I) coded pediatric deaths occurring between October 2004 and April 2010, excluding New York City (NYC) residents. A matching algorithm and capture-recapture analysis were used to estimate the total number of influenza-associated deaths among NYS children. Results. Thirty-four laboratory-confirmed influenza-associated pediatric deaths were reported and 67 death certificates had a P&I coded death; 16 deaths matched. No laboratory-confirmed influenza-associated death had a pneumonia code and no pneumonia coded deaths had laboratory evidence of influenza infection in their medical record. The capture-recapture analysis estimated between 38 and 126 influenza-associated pediatric deaths occurred in NYS during the study period. Conclusion. Passive surveillance for influenza-associated deaths continues to be the gold standard methodology for characterizing influenza mortality in children. Review of death certificates can complement but not replace passive reporting, by providing better estimates and detecting any missed laboratory-confirmed deaths.
    09/2012; 2012:397890. DOI:10.1155/2012/397890
  • Source
    • "Staphylococcal SBP is certainly a public health problem of great significance. In fact: (i) it accounted for 60–70% of SBP cases during the influenza pandemic of 1957 (Public Health Laboratory Service, 1957), causing more than 88,000 related excess deaths in the United States alone; (ii) S. aureus is reemerging as a major cause of fatal pneumonia in patients infected by both commonly circulating IAV (CDCP, 2004; Finelli et al., 2008; Podewils et al., 2005) and by the pandemic H1N1 strains of swine origin (Cheng et al., 2009; CDCP, 2009; Cohen and Enserink, 2009); (iii) S. aureus strains that circulate in the community and cause SBP strongly evolved virulence and antimicrobial resistance traits (Navarro et al., 2008). These data have made study of the IAV–S. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Secondary pneumonia caused by Staphylococcus aureus is reemerging as a primary cause of excess mortality associated with infection by the influenza A virus. We have investigated in vitro the cellular and molecular mechanisms underlying this synergism. Experimental data show a significant increase in the efficiency of internalisation of S. aureus into cultured pneumocytes during the early phases of viral infection, while a relevant increase in the efficiency of adhesion is evident only later during viral infection, suggesting that the 2 effects are based on different molecular mechanisms. Data reported in this paper show that S. aureus cells can bind the viral hemagglutinin (HA) and that this binding promotes enhanced bacterial internalisation by 2 mechanisms: binding to HA exposed at the surface of infected cells and binding to free extracellular virions, enabling internalisation at high efficiency also in cells that are not infected by the virus. The affinity of binding that involves S. aureus and HA was shown to be enhanced by the reducing extracellular environment that the virus can generate.
    International journal of medical microbiology: IJMM 10/2010; 301(2):97-104. DOI:10.1016/j.ijmm.2010.06.008 · 3.42 Impact Factor
Show more